|
KR20200115472A
|
|
Aminoadamantyl nitrate compounds and their use to treat CNS disorders
|
|
US6759416B2
|
|
Anticancer conjugates of camptothecin and unsaturated fatty acids
|
|
EP1389181A2
|
|
Antioxidant nitroxides and nitrones as therapeutic agents
|
|
AU3647501A
|
|
Circularly permutated, interaction-activated proteins
|
|
AU4183200A
|
|
A general method for optimizing the expression of heterologous proteins
|
|
CA2374476A1
|
|
Interaction-activated proteins
|
|
AU2979300A
|
|
Assay for asymmetrical dimethyl-L-arginine (ADMA)
|
|
US6103888A
|
|
Mammalian cationic proteins having lipopolysaccharide binding and anti-coagulant activity
|
|
AU2005099A
|
|
Methods and compositions for the treatment and prevention of (staphylococcus aureus) infections
|
|
AU7269098A
|
|
Cardiovascular disease risk assessment
|
|
US5952189A
|
|
Assay for inhibitors of a 24 kD cytoplasmic protease which activates DNA fragmentation in apoptosis
|
|
US5843937A
|
|
DNA-binding indole derivatives, their prodrugs and immunoconjugates as anticancer agents
|
|
US5618675A
|
|
Methods and compositions for detecting lipopolysaccharides using CAP18 fragments
|
|
AU7334994A
|
|
Use of esculentoside a for treatment of lipopolysaccharide and macrophage mediated disorders
|
|
US5605826A
|
|
24 kilodalton cytoplasmic protease activating DNA fragmentation in apoptosis
|
|
WO9402589A1
|
|
Mammalian cationic proteins having lipopolysaccharide binding and anti-coagulant activity
|
|
US5440022A
|
|
Hepatokine and methods for its use
|
